Ized CUmulative Survival trial, SYMPHONY for Sibrafiban versus aspirin to Yield Maximum Protection from ischemic Heart Events post acute corONary sYndrome, VIGOUR for VIrtual coordinating center for Global collaborative cardiOvascUlar
ثبت نشده
چکیده
loss of diurnal rhythm, in cortisol and leptin secretion. J Clin Endocrinol Metab 1998; 83: 280–3. [6] Anker SD, Ponikowski P, Varney S et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet 1997; 349: 1050–3. [7] Cleland JG, Clark AL. Leptin and cardiac cachexia: marker or mediator? Eur Heart J 1998; 19: 1421–2. [8] Poehlman ET, Scheffers J, Gottlieb SS, Fisher ML, Vaitekevicius P. Increased resting metabolic rate in patients with congestive heart failure. Ann Intern Med 1994; 121: 860–2. [9] Eisenhofer G, Friberg P, Rundqvist AA et al. Cardiac function in congestive heart failure. Circulation 1996; 93: 1667–76. [10] Fritsche A, Wahl HG, Metzinger E et al. Evidence for inhibition of leptin secretion by catecholamines in man. Exp Clin Endocrinol Diabetes 1998; 106: 415–8. [11] Böttner A, Eisenhofer G, Torpy DJ et al. Lack of leptin suppression in response to hypersecretion of catecholamines in pheochromocytoma patients. Metabolism 1999; [In Press].
منابع مشابه
Randomized Trial of Aspirin, Sibrafiban, or Both for Secondary Prevention After Acute Coronary Syndromes Second SYMPHONY Investigators Background—The first Sibrafiban Versus Aspirin to Yield Maximum Protection From Ischemic Heart Events Post–Acute Coronary Syndromes
Background—The first Sibrafiban Versus Aspirin to Yield Maximum Protection From Ischemic Heart Events Post–Acute Coronary Syndromes (SYMPHONY) trial showed no benefit of 2 doses of sibrafiban over aspirin for secondary prevention after acute coronary syndromes. In 2nd SYMPHONY, we compared low-dose sibrafiban plus aspirin (LDS1A), high-dose sibrafiban (HDS), and aspirin alone. Methods and Resul...
متن کاملRandomized Trial of Aspirin, Sibrafiban, or Both for Secondary Prevention After Acute Coronary Syndromes Second SYMPHONY Investigators Background—The first Sibrafiban Versus Aspirin to Yield Maximum Protection From Ischemic Heart Events Post–Acute Coronary Syndromes
Background—The first Sibrafiban Versus Aspirin to Yield Maximum Protection From Ischemic Heart Events Post–Acute Coronary Syndromes (SYMPHONY) trial showed no benefit of 2 doses of sibrafiban over aspirin for secondary prevention after acute coronary syndromes. In 2nd SYMPHONY, we compared low-dose sibrafiban plus aspirin (LDS1A), high-dose sibrafiban (HDS), and aspirin alone. Methods and Resul...
متن کاملMeeting highlights : highlights of the 49th scientific sessions of the american college of cardiology
Acute Coronary Syndromes The Trial: SYMPHONY II Presenter: Kristin Newby, Duke University Medical Center, Durham, NC. The study: A randomized trial of sibrafiban (an oral glycoprotein [GP] IIb/IIIa antagonist) in patients with acute coronary syndromes. The study was originally designed to include 8400 patients, but it was terminated prematurely by the sponsor (unilaterally) after the negative r...
متن کاملHighlights of the 49 th Scientific Sessions of the American College of Cardiology
Acute Coronary Syndromes The Trial: SYMPHONY II Presenter: Kristin Newby, Duke University Medical Center, Durham, NC. The study: A randomized trial of sibrafiban (an oral glycoprotein [GP] IIb/IIIa antagonist) in patients with acute coronary syndromes. The study was originally designed to include 8400 patients, but it was terminated prematurely by the sponsor (unilaterally) after the negative r...
متن کاملLessons learned from a clinical trial.
Remarkable advances in cardiovascular care have been substantially mediated by large-scale, randomized clinical trials. These trials not only have identified treatments resulting in major improvements in patient outcomes but also have enhanced our understanding of the natural history of contemporary disease and the impact of risk factors and complications. The process by which phase III clinica...
متن کامل